Search

Your search keyword '"Autio, Karen A."' showing total 285 results
Start Over Author "Autio, Karen A."
285 results on '"Autio, Karen A."'

1. Quality of life in the year after new diagnosis with advanced prostate cancer for Black and White individuals living in the US

Author

Rencsok, Emily M., Slopen, Natalie, Autio, Karen, Morgans, Alicia, McSwain, Lawrence, Barata, Pedro, Cheng, Heather H., Dreicer, Robert, Heath, Elisabeth, McKay, Rana R., Pomerantz, Mark, Rathkopf, Dana, Tagawa, Scott, Whang, Young E., Ragin, Camille, Odedina, Folakemi T., George, Daniel J., Kantoff, Philip W., Vinson, Jacob, Villanti, Paul, Haneuse, Sebastien, and Mucci, Lorelei A.

Published
2023
Full Text
View/download PDF

2. Immunologic and tumor responses of pegilodecakin with 5-FU/LV and oxaliplatin (FOLFOX) in pancreatic ductal adenocarcinoma (PDAC)

Author

Hecht, J Randolph, Papadopoulos, Kyriakos P, Falchook, Gerald S, Patel, Manish R, Infante, Jeffrey R, Aljumaily, Raid, Wong, Deborah J, Autio, Karen A, Wainberg, Zev A, Bauer, Todd M, Javle, Milind, Pant, Shubham, Bendell, Johanna, Hung, Annie, Ratti, Navneet, VanVlasselaer, Peter, Verma, Rakesh, Leveque, Joseph, Rao, Sujata, Oft, Martin, and Naing, Aung

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Clinical Trials and Supportive Activities, Cancer, Pancreatic Cancer, Clinical Research, Digestive Diseases, Rare Diseases, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Dose-Response Relationship, Drug, Fluorouracil, Humans, Interleukin-10, Kaplan-Meier Estimate, Leucovorin, Middle Aged, Neoplasm Staging, Organoplatinum Compounds, Pancreatic Neoplasms, Polyethylene Glycols, Progression-Free Survival, Response Evaluation Criteria in Solid Tumors, Metastatic pancreatic adenocarcinoma, Pegilodecakin, FOLFOX, Phase 1, IL-10, Pegylated IL-10, Pharmacology and Pharmaceutical Sciences, Oncology & Carcinogenesis, Oncology and carcinogenesis, Pharmacology and pharmaceutical sciences
Abstract

Background Treatment options for pancreatic ductal adenocarcinoma (PDAC) are limited and checkpoint blockade inhibitors have been disappointing in this disease. Pegilodecakin has demonstrated single agent anti-tumor activity in immune-sensitive tumors. Phase 1 and preclinical data indicate synergy of pegilodecakin with 5-FU and platins. We assessed the safety and activity of pegilodecakin+FOLFOX in patients with PDAC. Methods IVY (NCT02009449) was an open-label phase 1b trial in the United States. Here we report on all enrolled patients from cohort C. Heavily pretreated patients were treated with pegilodecakin (self-administered subcutaneously daily at 2.5, 5, or 10 μg/kg) + 5-flurouracil/leucovorin/oxaliplatin (FOLFOX), dosed per manufacturers prescribing information, until tumor progression. Eligible patients had measurable disease per immune-related response criteria (irRC), were ≥ 18 years of age, and had ECOG performance status of 0 or 1. Patients were evaluated for primary(safety) and secondary (tumor response per irRC) endpoints. Results From 5 August 2014-12 July 2016, 39 patients enrolled in cohort C. All patients were evaluable for safety. In this advanced population, regimen had manageable toxicities with no immune-related adverse events (irAEs) greater than grade 1. The most common grade 3/4/5 TEAEs were thrombocytopenia (21[53.8%] of 39) and anemia (17[43.6%] of 39). In evaluable PDAC patients, the best overall response of pegilodecakin+FOLFOX was 3(14%) with CRs in 2(9%) patients. Conclusions Pegilodecakin+FOLFOX had an acceptable tolerability profile in PDAC, with no substantial irAEs seen, and promising efficacy with the combination yielding a 2-year OS of 24% (95% CI 10-42). These data led to the phase 3 study with pegilodecakin+FOLFOX as second-line therapy of PDAC (SEQUOIA).

Published
2021

3. Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial

Author

Naing, Aung, Wong, Deborah J, Infante, Jeffrey R, Korn, W Michael, Aljumaily, Raid, Papadopoulos, Kyriakos P, Autio, Karen A, Pant, Shubham, Bauer, Todd M, Drakaki, Alexandra, Daver, Naval G, Hung, Annie, Ratti, Navneet, McCauley, Scott, Van Vlasselaer, Peter, Verma, Rakesh, Ferry, David, Oft, Martin, Diab, Adi, Garon, Edward B, and Tannir, Nizar M

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Lung, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, 6.1 Pharmaceuticals, Good Health and Well Being, Aged, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Female, Humans, Interleukin-10, Male, Middle Aged, Neoplasms, Nivolumab, Polyethylene Glycols, Programmed Cell Death 1 Receptor, United States, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

BackgroundIL-10 has anti-inflammatory and CD8+ T-cell stimulating activities. Pegilodecakin (pegylated IL-10) is a first-in-class, long-acting IL-10 receptor agonist that induces oligoclonal T-cell expansion and has single-agent activity in advanced solid tumours. We assessed the safety and activity of pegilodecakin with anti-PD-1 monoclonal antibody inhibitors in patients with advanced solid tumours.MethodsWe did a multicentre, multicohort, open-label, phase 1b trial (IVY) at 12 cancer research centres in the USA. Patients were assigned sequentially into cohorts. Here, we report on all enrolled patients from two cohorts treated with pegilodecakin combined with anti-PD-1 inhibitors. Eligible patients were aged at least 18 years with histologically or cytologically confirmed advanced malignant solid tumours refractory to previous therapies, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients with uncontrolled infectious diseases were excluded. Pegilodecakin was provided in single-use 3 mL vials and was self-administered subcutaneously by injection at home at 10 μg/kg or 20 μg/kg once per day in combination with pembrolizumab (2 mg/kg every 3 weeks or 200 mg every 3 weeks) or nivolumab (3 mg/kg every 2 weeks or 240 mg every 2 weeks or 480 mg every 4 weeks at the approved dosing), both of which were given intravenously at the study site. Patients received pembrolizumab or nivolumab with pegilodecakin until disease progression, toxicity necessitating treatment discontinuation, patient withdrawal of consent, or study end. The primary endpoints were safety and tolerability, assessed in all patients enrolled in the study who received any amount of study medication including at least one dose of pegilodecakin, and pharmacokinetics (previously published). Secondary endpoints included objective response by immune-related response criteria in all patients who were treated and had evaluable measurements. The study is active but no longer recruiting, and is registered with ClinicalTrials.gov, NCT02009449.FindingsBetween Feb 13, 2015, and Sept 12, 2017, 111 patients were enrolled in the two cohorts. 53 received pegilodecakin plus pembrolizumab, and 58 received pegilodecakin plus nivolumab. 34 (31%) of 111 patients had non-small-cell lung cancer, 37 (33%) had melanoma, and 38 (34%) had renal cell carcinoma; one (

Published
2019

4. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer

Author

Truong, Hong, Breen, Kelsey, Nandakumar, Subhiksha, Sjoberg, Daniel D., Kemel, Yelena, Mehta, Nikita, Lenis, Andrew T., Reisz, Peter A., Carruthers, Jessica, Benfante, Nicole, Joseph, Vijai, Khurram, Aliya, Gopalan, Anuradha, Fine, Samson W., Reuter, Victor E., Vickers, Andrew J., Birsoy, Ozge, Liu, Ying, Walsh, Michael, Latham, Alicia, Mandelker, Diana, Stadler, Zsofia K., Pietzak, Eugene, Ehdaie, Behfar, Touijer, Karim A., Laudone, Vincent P., Slovin, Susan F., Autio, Karen A., Danila, Daniel C., Rathkopf, Dana E., Eastham, James A., Chen, Yu, Morris, Michael J., Offit, Kenneth, Solit, David B., Scher, Howard I., Abida, Wassim, Robson, Mark E., and Carlo, Maria I.

Published
2023
Full Text
View/download PDF

6. Supplementary Methods S1 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Table S3 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Figure S2 from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

9. Data from A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., primary, Autio, Karen, primary, Bernard-Tessier, Alice, primary, Rettig, Matthew B., primary, Machiels, Jean-Pascal, primary, Bilen, Mehmet A., primary, Lolkema, Martijn P., primary, Adra, Nabil, primary, Rottey, Sylvie, primary, Greil, Richard, primary, Matsubara, Nobuaki, primary, Tan, Daniel S.W., primary, Wong, Alvin, primary, Uemura, Hiroji, primary, Lemech, Charlotte, primary, Meran, Johannes, primary, Yu, Youfei, primary, Minocha, Mukul, primary, McComb, Mason, primary, Penny, Hweixian Leong, primary, Gupta, Vinita, primary, Hu, Xuguang, primary, Jurida, Gabor, primary, Kouros-Mehr, Hosein, primary, Janát-Amsbury, Margit M., primary, Eggert, Tobias, primary, and Tran, Ben, primary

Published
2024
Full Text
View/download PDF

10. PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients

Author

Naing, Aung, Infante, Jeffrey R, Papadopoulos, Kyriakos P, Chan, Ivan H, Shen, Cong, Ratti, Navneet P, Rojo, Bianca, Autio, Karen A, Wong, Deborah J, Patel, Manish R, Ott, Patrick A, Falchook, Gerald S, Pant, Shubham, Hung, Annie, Pekarek, Kara L, Wu, Victoria, Adamow, Matthew, McCauley, Scott, Mumm, John B, Wong, Phillip, Van Vlasselaer, Peter, Leveque, Joseph, Tannir, Nizar M, and Oft, Martin

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Cancer, Animals, Antineoplastic Agents, CD8-Positive T-Lymphocytes, Cell Proliferation, Cells, Cultured, Granzymes, Humans, Immunotherapy, Interferon-gamma, Interleukin-10, Interleukin-18, Lymphocyte Activation, Lymphocytes, Tumor-Infiltrating, Mice, Mice, Inbred C57BL, Neoplasms, Polyethylene Glycols, Programmed Cell Death 1 Receptor, AM0010, CD8(+) T cell, IL-10, PEGylated Interleukin 10, T cell invigoration, Th1, clinical trial, clonal expansion, clonality, pegilodecakin, Neurosciences, Oncology & Carcinogenesis, Biochemistry and cell biology, Oncology and carcinogenesis
Abstract

Tumor-reactive T cell exhaustion prevents the success of immune therapies. Pegilodecakin activates intratumoral CD8+ T cells in mice and induces objective tumor responses in patients. Here we report that pegilodecakin induces hallmarks of CD8+ T cell immunity in cancer patients, including elevation of interferon-γ and GranzymeB, expansion and activation of intratumoral CD8+ T cells, and proliferation and expansion of LAG-3+ PD-1+ CD8+ T cells. On pegilodecakin, newly expanded T cell clones, undetectable at baseline, become 1%-10% of the total T cell repertoire in the blood. Elevation of interleukin-18, expansion of LAG-3+ PD-1+ T cells and novel T cell clones each correlated with objective tumor responses. Combined pegilodecakin with anti-PD-1 increased the expansion of LAG-3+ PD-1+ CD8+ T cells.

Published
2018

11. Randomized Phase 2 Trial of Abiraterone Acetate Plus Prednisone, Degarelix, or the Combination in Men with Biochemically Recurrent Prostate Cancer After Radical Prostatectomy

Author

Autio, Karen A., Antonarakis, Emmanuel S., Mayer, Tina M., Shevrin, Daniel H., Stein, Mark N., Vaishampayan, Ulka N., Morris, Michael J., Slovin, Susan F., Heath, Elisabeth I., Tagawa, Scott T., Rathkopf, Dana E., Milowsky, Matthew I., Harrison, Michael R., Beer, Tomasz M., Balar, Arjun V., Armstrong, Andrew J., George, Daniel J., Paller, Channing J., Apollo, Arlyn, Danila, Daniel C., Graff, Julie N., Nordquist, Luke, Dayan Cohn, Erica S., Tse, Kin, Schreiber, Nicole A., Heller, Glenn, and Scher, Howard I.

Published
2021
Full Text
View/download PDF

12. FIGURE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

13. Data from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

14. Data from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

15. Supplementary Table 1. from Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., primary, Ericsson, Caroline I., primary, Vaselkiv, Jane B., primary, Rencsok, Emily M., primary, Stopsack, Konrad H., primary, Guard, Hannah E., primary, Autio, Karen A., primary, Rathkopf, Dana E., primary, Enting, Deborah, primary, Bitting, Rhonda L., primary, Mateo, Joaquin, primary, Githiaka, Charles W., primary, Chi, Kim N., primary, Cheng, Heather H., primary, Davis, Ian D., primary, Anderson, Simon G., primary, Badal, Simone Ann Marie, primary, Bjartell, Anders, primary, Russnes, Kjell M., primary, Heath, Elisabeth I., primary, Pomerantz, Mark M., primary, Henegan, John C., primary, Hyslop, Terry, primary, Esteban, Emilio, primary, Omlin, Aurelius, primary, McDermott, Ray, primary, Fay, Andre P., primary, Popoola, Ademola Alabi, primary, Ragin, Camille, primary, Nowak, Joel, primary, Gerke, Travis, primary, Kantoff, Philip W., primary, George, Daniel J., primary, Penney, Kathryn L., primary, and Mucci, Lorelei A., primary

Published
2024
Full Text
View/download PDF

16. A phase 1 study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer

Author

Dorff, Tanya, primary, Horvath, Lisa G., additional, Autio, Karen, additional, Bernard-Tessier, Alice, additional, Rettig, Matthew B., additional, Machiels, Jean-Pascal, additional, Bilen, Mehmet A., additional, Lolkema, Martijn P., additional, Adra, Nabil, additional, Rottey, Sylvie, additional, Greil, Richard, additional, Matsubara, Nobuaki, additional, Tan, Daniel S.W., additional, Wong, Alvin, additional, Uemura, Hiroji, additional, Lemech, Charlotte, additional, Meran, Johannes, additional, Yu, Youfei, additional, Minocha, Mukul, additional, McComb, Mason, additional, Penny, Hweixian Leong., additional, Gupta, Vinita, additional, Hu, Xuguang, additional, Jurida, Gabor, additional, Kouros-Mehr, Hosein, additional, Janát-Amsbury, Margit M., additional, Eggert, Tobias, additional, and Tran, Ben, additional

Published
2024
Full Text
View/download PDF

17. FIGURE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

18. Supplementary Table S4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure S2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

20. TABLE 1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

21. TABLE 3 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

22. TABLE 4 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

23. TABLE 2 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

24. Marital status, living arrangement, and survival among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, Guard, Hannah E., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Enting, Deborah, additional, Bitting, Rhonda L., additional, Mateo, Joaquin, additional, Githiaka, Charles Waihenya., additional, Chi, Kim N., additional, Cheng, Heather H., additional, Davis, Ian D., additional, Anderson, Simon G., additional, Badal, Simone Ann Marie., additional, Bjartell, Anders, additional, Russnes, Kjell M., additional, Heath, Elisabeth I., additional, Pomerantz, Mark M., additional, Henegan, John C., additional, Hyslop, Terry, additional, Esteban, Emilio, additional, Omlin, Aurelius, additional, McDermott, Ray, additional, Fay, Andre P., additional, Popoola, Ademola Alabi., additional, Ragin, Camille, additional, Nowak, Joel, additional, Gerke, Travis, additional, Kantoff, Philip W., additional, George, Daniel J., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2024
Full Text
View/download PDF

25. Supplementary Methods S1 from Pain and Its Association with Survival for Black and White Individuals with Advanced Prostate Cancer in the United States

Author

Rencsok, Emily M., primary, Slopen, Natalie, primary, McManus, Hannah D., primary, Autio, Karen A., primary, Morgans, Alicia K., primary, McSwain, Lawrence, primary, Barata, Pedro, primary, Cheng, Heather H., primary, Dreicer, Robert, primary, Gerke, Travis, primary, Green, Rebecca, primary, Heath, Elisabeth I., primary, Howard, Lauren E., primary, McKay, Rana R., primary, Nowak, Joel, primary, Pileggi, Shannon, primary, Pomerantz, Mark M., primary, Rathkopf, Dana E., primary, Tagawa, Scott T., primary, Whang, Young E., primary, Ragin, Camille, primary, Odedina, Folakemi T., primary, Kantoff, Philip W., primary, Vinson, Jake, primary, Villanti, Paul, primary, Haneuse, Sebastien, primary, Mucci, Lorelei A., primary, and George, Daniel J., primary

Published
2024
Full Text
View/download PDF

27. High-risk prostate cancer—classification and therapy

Author

Chang, Albert J, Autio, Karen A, Roach, Mack, and Scher, Howard I

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Aging, Cancer, Prostate Cancer, Urologic Diseases, Humans, Male, Prognosis, Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant, Risk Factors, Treatment Outcome, Oncology and carcinogenesis
Abstract

Approximately 15% of patients with prostate cancer are diagnosed with high-risk disease. However, the current definitions of high-risk prostate cancer include a heterogeneous group of patients with a range of prognoses. Some have the potential to progress to a lethal phenotype that can be fatal, while others can be cured with treatment of the primary tumour alone. The optimal management of this patient subgroup is evolving. A refined classification scheme is needed to enable the early and accurate identification of high-risk disease so that more-effective treatment paradigms can be developed. We discuss several principles established from clinical trials, and highlight other questions that remain unanswered. This Review critically evaluates the existing literature focused on defining the high-risk population, the management of patients with high-risk prostate cancer, and future directions to optimize care.

Published
2014

28. Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Author

Naiyu Chen, McGrath, Colleen B., Ericsson, Caroline I., Vaselkiv, Jane B., Rencsok, Emily M., Stopsack, Konrad H., Guard, Hannah E., Autio, Karen A., Rathkopf, Dana E., Enting, Deborah, Bitting, Rhonda L., Mateo, Joaquin, Githiaka, Charles W., Chi, Kim N., Cheng, Heather H., Davis, Ian D., Anderson, Simon G., Badal, Simone Ann Marie, Bjartell, Anders, and Russnes, Kjell M.

Abstract

Background: Studies have shown improved survival among individuals with cancer with higher levels of social support. Few studies have investigated social support and overall survival (OS) in individuals with advanced prostate cancer in an international cohort. We investigated the associations of marital status and living arrangements with OS among individuals with advanced prostate cancer in the International Registry for Men with Advanced Prostate Cancer (IRONMAN). Methods: IRONMAN is enrolling participants diagnosed with advanced prostate cancer (metastatic hormone-sensitive prostate cancer, mHSPC; castration-resistant prostate cancer, CRPC) from 16 countries. Participants in this analysis were recruited between July 2017 and January 2023. Adjusting for demographics and tumor characteristics, the associations were estimated using Cox regression and stratified by disease state (mHSPC, CRPC), age (<70, =70 years), and continent of enrollment (North America, Europe, Other). Results: We included 2,119 participants with advanced prostate cancer, of whom 427 died during up to 5 years of follow-up (median 6 months). Two-thirds had mHSPC. Most were married/in a civil partnership (79%) and 6% were widowed. Very few married participants were living alone (1%), while most unmarried participants were living alone (70%). Married participants had better OS than unmarried participants [adjusted HR: 1.44; 95% confidence interval (CI): 1.02-2.02]. Widowed participants had the worst survival compared with married individuals (adjusted HR: 1.89; 95% CI: 1.22-2.94). Conclusions: Among those with advanced prostate cancer, unmarried and widowed participants had worse OS compared with married participants. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Clinical Impact of a Rapid Genetic Testing Model for Advanced Prostate Cancer Patients

Author

Breen, Kelsey E., primary, Symecko, Heather, additional, Spielman, Kelsey, additional, Gebert, Rebecca, additional, Shah, Ibrahim H., additional, Pundock, Stacy, additional, Batson, Melissa, additional, Narayan, Vivek K., additional, Stadler, Zsofia K., additional, Autio, Karen A., additional, Abida, Wassim, additional, Danila, Daniel C., additional, Scher, Howard I., additional, Morris, Michael J., additional, Hamilton, Jada G., additional, Robson, Mark E., additional, Domchek, Susan M., additional, and Carlo, Maria I., additional

Published
2023
Full Text
View/download PDF

30. Abstract 941: Assessment of the completeness, accuracy, and scalability of commercial abstraction for a large prostate cancer biospecimen repository

Author

Carbone, Emily A., primary, Barnett, Ethan S., additional, Keegan, Niamh M., additional, Vasselman, Samantha E., additional, Nweji, Barbara, additional, Gajar, Ria N., additional, Autio, Karen A., additional, Abida, Wassim, additional, Scher, Howard I., additional, and Stopsack, Konrad H., additional

Published
2023
Full Text
View/download PDF

31. Abstract 6489: Marital status, living arrangement, and overall survival among individuals with advanced prostate cancer in the IRONMAN cohort

Author

Chen, Naiyu, primary, McGrath, Colleen B., additional, Ericsson, Caroline I., additional, Vaselkiv, Jane B., additional, Sodipo, Michelle O., additional, Rencsok, Emily M., additional, Stopsack, Konrad H., additional, George, Daniel J., additional, Autio, Karen A., additional, Rathkopf, Dana E., additional, Penney, Kathryn L., additional, and Mucci, Lorelei A., additional

Published
2023
Full Text
View/download PDF

32. Supplementary Table S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Figure from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

34. Supplementary Figure S2 from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Materials and Methods from Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study

Author

Autio, Karen A., primary, Klebanoff, Christopher A., primary, Schaer, David, primary, Kauh, John Sae Wook, primary, Slovin, Susan F., primary, Adamow, Matthew, primary, Blinder, Victoria S., primary, Brahmachary, Manisha, primary, Carlsen, Michelle, primary, Comen, Elizabeth, primary, Danila, Daniel C., primary, Doman, Thompson N., primary, Durack, Jeremy C., primary, Fox, Josef J., primary, Gluskin, Jill S., primary, Hoffman, David M., primary, Kang, Suhyun, primary, Kang, Praneet, primary, Landa, Jonathan, primary, McAndrew, Philomena F., primary, Modi, Shanu, primary, Morris, Michael J., primary, Novosiadly, Ruslan, primary, Rathkopf, Dana E., primary, Sanford, Rachel, primary, Chapman, Sonya C., primary, Tate, Courtney M., primary, Yu, Danni, primary, Wong, Phillip, primary, and McArthur, Heather L., primary

Published
2023
Full Text
View/download PDF

37. Data from Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, primary, Arora, Kanika, primary, Nguyen, Bastien, primary, Vasselman, Samantha E., primary, Nweji, Barbara, primary, McBride, Sean M., primary, Morris, Michael J., primary, Rathkopf, Dana E., primary, Slovin, Susan F., primary, Danila, Daniel C., primary, Autio, Karen A., primary, Scher, Howard I., primary, Mucci, Lorelei A., primary, Solit, David B., primary, Gönen, Mithat, primary, Chen, Yu, primary, Berger, Michael F., primary, Schultz, Nikolaus, primary, Abida, Wassim, primary, and Kantoff, Philip W., primary

Published
2023
Full Text
View/download PDF

38. First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1)

Author

Postel-Vinay, Sophie, primary, Lam, Vincent K, additional, Ros, Willeke, additional, Bauer, Todd M, additional, Hansen, Aaron R, additional, Cho, Daniel C, additional, Stephen Hodi, F, additional, Schellens, Jan H M, additional, Litton, Jennifer K, additional, Aspeslagh, Sandrine, additional, Autio, Karen A, additional, Opdam, Frans L, additional, McKean, Meredith, additional, Somaiah, Neeta, additional, Champiat, Stephane, additional, Altan, Mehmet, additional, Spreafico, Anna, additional, Rahma, Osama, additional, Paul, Elaine M, additional, Ahlers, Christoph M, additional, Zhou, Helen, additional, Struemper, Herbert, additional, Gorman, Shelby A, additional, Watmuff, Maura, additional, Yablonski, Kaitlin M, additional, Yanamandra, Niranjan, additional, Chisamore, Michael J, additional, Schmidt, Emmett V, additional, Hoos, Axel, additional, Marabelle, Aurelien, additional, Weber, Jeffrey S, additional, and Heymach, John V, additional

Published
2023
Full Text
View/download PDF

39. First-in-human, phase 1 study of PF-06753512, a vaccine-based immunotherapy regimen (VBIR), in non-metastatic hormone-sensitive biochemical recurrence and metastatic castration-resistant prostate cancer (mCRPC)

Author

Autio, Karen A, primary, Higano, Celestia S, additional, Nordquist, Luke, additional, Appleman, Leonard J, additional, Zhang, Tian, additional, Zhu, Xin-Hua, additional, Babiker, Hani, additional, Vogelzang, Nicholas J, additional, Prasad, Sandip M, additional, Schweizer, Michael T, additional, Madan, Ravi A, additional, Billotte, Stephane, additional, Cavazos, Nora, additional, Bogg, Orlaith, additional, Li, Ray, additional, Chan, Kam, additional, Cho, Helen, additional, Kaneda, Megan, additional, Wang, I-Ming, additional, Zheng, Jenny, additional, Tang, Szu-Yu, additional, Hollingsworth, Robert, additional, Kern, Kenneth A, additional, and Petrylak, Daniel P, additional

Published
2023
Full Text
View/download PDF

41. 555 Clinical and pharmacodynamic biomarker results from PORTER, a multi-cohort phase 1 platform trial of combination immunotherapy for metastatic castration-resistant prostate cancer patients

Author

Galsky, Matthew, primary, Autio, Karen, additional, Wentzel, Kristopher, additional, Graff, Julie, additional, Friedlander, Terence, additional, Densmore, Julie, additional, Cabanski, Christopher, additional, Shotts, Kristin, additional, Howes, Tim, additional, Yu, Jia, additional, Eisenbeisz, Elaine, additional, Spasic, Marko, additional, Maddock, Stephen, additional, DaSilva, Diane, additional, Kumar, Dinesh, additional, Moore, Jonni, additional, Schretzenmair, Richard, additional, Lata, Jennifer, additional, Xu, Arron, additional, Reuschel, Emma, additional, Wani, Snehal, additional, Morrow, Matthew, additional, Skolnik, Jeffrey, additional, Santulli-Marotto, Sandra, additional, Padron, Lacey, additional, Butterfield, Lisa, additional, LaVallee, Theresa, additional, Bucktrout, Samantha, additional, Yellin, Michael, additional, Keler, Tibor, additional, Salvador, Lisa, additional, O'Donnell-Tormey, Jill, additional, Lucey, Vanessa, additional, Fairchild, Justin, additional, Dugan, Ute, additional, Bhardwaj, Nina, additional, Subudhi, Sumit, additional, and Fong, Lawrence, additional

Published
2022
Full Text
View/download PDF

42. 559 Biomarker correlates of clinical response with FLT3L/nivo backbone treatment in the multi-cohort phase 1 PORTER platform trial in metastatic castration-resistant prostate cancer patients

Author

Shotts, Kristin, primary, Howes, Timothy, additional, Yu, Jia, additional, Densmore, Julie, additional, Silva, Diane Da, additional, Kumar, Dinesh, additional, Santulli-Marotto, Sandra, additional, Cabanski, Christopher, additional, Eisenbeisz, Elaine, additional, Ivison, Geoffrey, additional, Mayer, Aaron, additional, Moore, Jonni, additional, Jones, Derek, additional, Kraynyak, Kimberly, additional, Dolgoter, Alex, additional, Chen, Richard, additional, Butterfield, Lisa, additional, LaVallee, Theresa, additional, Bucktrout, Samantha, additional, Padron, Lacey, additional, Dugan, Ute, additional, Yellin, Michael, additional, Keler, Tibor, additional, O'Donnell-Tormey, Jill, additional, Fairchild, Justin, additional, Salvador, Lisa, additional, Wentzel, Kristopher, additional, Fong, Lawrence, additional, Subudhi, Sumit, additional, Bhardwaj, Nina, additional, Autio, Karen, additional, and Galsky, Matthew, additional

Published
2022
Full Text
View/download PDF

43. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial

Author

Basch, Ethan, Autio, Karen, Ryan, Charles J, Mulders, Peter, Shore, Neal, Kheoh, Thian, Fizazi, Karim, Logothetis, Christopher J, Rathkopf, Dana, Smith, Matthew R, Mainwaring, Paul N, Hao, Yanni, Griffin, Thomas, Li, Susan, Meyers, Michael L, Molina, Arturo, and Cleeland, Charles

Published
2013
Full Text
View/download PDF

45. Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality

Author

Keegan, Niamh M., primary, Vasselman, Samantha E., additional, Barnett, Ethan S., additional, Nweji, Barbara, additional, Carbone, Emily A., additional, Blum, Alexander, additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Scher, Howard I., additional, Kantoff, Philip W., additional, Abida, Wassim, additional, and Stopsack, Konrad H., additional

Published
2022
Full Text
View/download PDF

46. Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors

Author

Stopsack, Konrad H., primary, Nandakumar, Subhiksha, additional, Arora, Kanika, additional, Nguyen, Bastien, additional, Vasselman, Samantha E., additional, Nweji, Barbara, additional, McBride, Sean M., additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Scher, Howard I., additional, Mucci, Lorelei A., additional, Solit, David B., additional, Gönen, Mithat, additional, Chen, Yu, additional, Berger, Michael F., additional, Schultz, Nikolaus, additional, Abida, Wassim, additional, and Kantoff, Philip W., additional

Published
2021
Full Text
View/download PDF

47. Clinical Annotations for Prostate Cancer Research: Defining Data Elements, Creating a Reproducible Analytical Pipeline, and Assessing Data Quality

Author

Keegan, Niamh M., primary, Vasselman, Samantha E., additional, Barnett, Ethan S., additional, Nweji, Barbara, additional, Carbone, Emily A., additional, Blum, Alexander, additional, Morris, Michael J., additional, Rathkopf, Dana E., additional, Slovin, Susan F., additional, Danila, Daniel C., additional, Autio, Karen A., additional, Kantoff, Philip W., additional, Abida, Wassim, additional, and Stopsack, Konrad H., additional

Published
2021
Full Text
View/download PDF

48. MP24-01 RESPONSE TO IMMUNE CHECKPOINT BLOCKADE IN PATIENTS WITH MICROSATELLITE INSTABLE AND HIGH TUMOR MUTATIONAL BURDEN PROSTATE CANCER

Author

Lenis, Andrew T., primary, Ravichandran, Vignesh, additional, Truong, Hong, additional, Reisz, Peter, additional, Nweji, Barbara, additional, Autio, Karen, additional, Morris, Michael, additional, Slovin, Susan, additional, Vargas, Hebert Alberto, additional, Laudone, Vincent, additional, Ehdaie, Behfar, additional, Reuter, Victor, additional, Viale, Agnes, additional, Schultz, Nikolaus, additional, Gopalan, Anuradha, additional, Donoghue, Mark, additional, Stopsack, Konrad, additional, Solit, David, additional, and Abida, Wassim, additional

Published
2021
Full Text
View/download PDF

49. CX-072 (pacmilimab), a Probody®PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study

Author

Naing, Aung, primary, Thistlethwaite, Fiona, additional, De Vries, Elisabeth G.E., additional, Eskens, Ferry A.L.M., additional, Uboha, Nataliya, additional, Ott, Patrick A., additional, LoRusso, Patricia, additional, Garcia-Corbacho, Javier, additional, Boni, Valentina, additional, Bendell, Johanna, additional, Autio, Karen A., additional, Randhawa, Manreet, additional, Durm, Greg, additional, Gil-Martin, Marta, additional, Stroh, Mark, additional, Hannah, Alison L., additional, Arkenau, Hendrik-Tobias, additional, and Spira, Alexander, additional

Published
2021
Full Text
View/download PDF

50. CX-072 (pacmilimab), a Probody PD-L1 inhibitor, in combination with ipilimumab in patients with advanced solid tumors (PROCLAIM-CX-072): a first-in-human, dose-finding study

Author

Sanborn, Rachel E, primary, Hamid, Omid, additional, de Vries, Elisabeth GE, additional, Ott, Patrick A, additional, Garcia-Corbacho, Javier, additional, Boni, Valentina, additional, Bendell, Johanna, additional, Autio, Karen A, additional, Cho, Daniel C, additional, Plummer, Ruth, additional, Stroh, Mark, additional, Lu, Lawrence, additional, and Thistlethwaite, Fiona, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results